Cerecor Announces CERC-002 Significantly Reduced Respiratory Failure and Mortality in Phase 2 Clinical Trial in Patients Hospitalized with COVID-19 ARDS

    NEXT STORY
    Myriad Genetics Joins Forces with Intermountain Precision Genomics for a Comprehensive Offering of Germline and Somatic Tumor Testing Services
    PREV STORY
    G1 Therapeutics and Boehringer Ingelheim Announce Commercial Availability of COSELA™ (trilaciclib), the Only FDA-Approved Multilineage Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Project HOPE Says Health Needs Persist after Harvey and Irma

    Millwood, VA, Sept. 15, 2017 (GLOBE NEWSWIRE) -- Hurricane Harvey may no longer be ...

    author_avatar
    NASDAQ Market News

    TG Therapeutics, Inc. Announces Publication of Clinical Data from the Phase 1 First-in-Human Trial of Umbralisib in The Lancet Oncology

    Umbralisib is structurally distinct from other PI3K delta inhibitors with greater selectivity to PI3K ...

    author_avatar
    NASDAQ Market News

    One Medical Announces Results for Second Quarter 2020

    author_avatar
    NASDAQ Market News